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Abstract
Background: Radiofrequency ablation (RFA) is a relatively new technique, applied to metastatic solid
tumours which, in recent studies, has been shown to be feasible and safe on locally advanced pancreatic
carcinoma (LAPC). RFA can be combined with radio-chemotherapy (RCT) and intra-arterial plus systemic
chemotherapy (IASC). The aim of this study was to investigate the impact on the prognosis of a
multimodal approach to LAPC and define the best timing of RFA.
Methods: This is a retrospective observational study of patients who have consecutively undergone RFA
associated with multiple adjuvant approaches.
Results: Between February 2007 and December 2011, 168 consecutive patients were treated by RFA,
of which 107 were eligible for at least 18 months of follow-up. Forty-seven patients (group 1) underwent
RFA as an up-front treatment and 60 patients as second treatment (group 2) depending on clinician
choice. The median overall survival (OS) of the whole series was 25.6 months: 14.7 months in the group
1 and 25.6 months in the group 2 (P = 0.004). Those patients who received the multimodal treatment (RFA,
RCT and IASC-triple approach strategy) had an OS of 34.0 months.
Conclusions: The multimodal approach seems to be feasible and associated with an improved longer
survival rate.
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Introduction
Pancreatic cancer is usually associated with an unfavourable
outcome in spite of multiple approaches. Its poor prognosis is
related to an aggressive biological behaviour and to the high rate
of metastatic stage at diagnosis.
Surgery with radical intent can be applied in 20% of patients
with pancreatic cancer whereas the remainder are usually consid-
ered for palliative adjuvant therapy. The addition of chemo-
therapy has achieved only a modest survival benefit leading to the
evaluation of novel interventions.1–6 The evidence of an unex-
pected high rate of recurrence after resection even for early stage
disease suggests that pancreatic adenocarcinoma is a systemic
disease from the outset.7 Locally advanced pancreatic carcinoma
associated with vascular involvement, is still a matter of debate in
terms of definition and better therapeutic approaches. Many
therapeutic options have been suggested: extended radical surgery
with vascular grafts, aggressive chemo and/or radiotherapy and
ablative therapies but a definitive protocol has not yet been
approved.
RFA is a relatively new technology, which is usually applied to
unresectable solid tumours for palliation. RFA applied to locally
advanced pancreatic carcinomahas shown to be feasible and safe.8,9
Up until now, systemic chemotherapy followed by radiotherapy
represents the gold standard treatment.10 Radio-chemotherapy
(RCT) can increase local control of the disease and intra-arterial
chemotherapy has been considered to reduce progression in the
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liver.11–14 The primary aim of the study was to test different treat-
ments associated with RFA in locally advanced pancreatic cancer
patients to determine whether this is an effective multimodal
approach. The secondary aim was to investigate the role of intra-
arterial and systemic chemotherapy (IASC) combined with abla-
tive debulking by RFA.
Patients and methods
All consecutive patients affected by a histologically proven locally
advanced pancreatic cancer presenting to the Pancreatic Unit,
Pederzoli Clinic, Peschiera del Garda (VR) were enrolled for RFA
from 1st February 2007 to 31st December 2011. Application of
RFA in this context was approved by the Ethical Committee of
Verona University and a local committee. Written informed
consent was obtained from all patients. Information on all
patients was recorded on the unit database.
Patients were included with the following criteria: age between
18 and 80 years, pre-operative staging [ultrasonography (US),
abdominal computed tomography (CT) or magnetic resonance
imaging] diagnostic for an unresectable non-metastatic pancre-
atic solid mass, pre-treatment cytology positive for pancreatic
carcinoma on expert pathologist opinion, the absence of distant
metastases and an Eastern Cooperative Oncology Group (ECOG)
performance status of 0 or 1. Exclusion criteria were: contraindi-
cations to surgery and the presence of multiple pancreatic lesions,
and metastatic disease. Pre-treatment evaluation included
medical history, physical examination, body weight, complete
blood cell count, biochemical profile, a carbohydrate antigen 19-9
(CA 19-9) value and electrocardiogram. Follow-up, including
clinical examination, body weight, complete blood cell count, bio-
chemical profile, CA 19-9 level, abdominal US and CT, was
planned after 30 days and every 3 months thereafter.
Treatments
The RFA procedure has been widely described in a previous
paper.8 During a laparotomy, exploration of the peritoneal cavity
is performed to detect misdiagnosed metastatic malignancies and
intra-operative US is utilized to confirm unresectability and to
exclude liver metastases. A biliary and/or gastric bypass was per-
formed for jaundice and/or duodenal obstruction when required.
A soft abdominal drain was left near the site of RFA probe inser-
tion to detect pancreatic fistulae. After the procedure, patients
were assessed daily for evidence of acute pancreatitis, bleeding,
pancreatic fistulae and infection.
Patients were considered for different adjuvant approaches
depending on clinician choice and general conditions. Radio-
therapy was delivered as an external beam radiation at a dose of
54.0–59.4 Gy. Chemotherapy involved the use of gemcitabine
administered weekly on Tuesdays and Fridays at a daily dose of
40 mg/m2 through the entire course of radiotherapy. Gemcitabine
was suspended for haematological toxicity greater than grade 1
until haematological recovery occurred.
Intra-arterial chemotherapy combined with systemic chemo-
therapy consisted of: day 1, epirubicin 35 mg/m2 and cisplatin
42 mg/m2 via the coeliac axis by bolus injection through a catheter
inserted in the femoral artery. Gemcitabine was administered on
day 2 of each cycle at a dose of 1000 mg/m2 (intravenously, over
30 min). Capecitabine was given orally at the dose of 650 mg/m2
twice a day, on days 2–15. Cycles were repeated every 28 days until
progression of disease, unacceptable toxicity or withdrawal of
patient consent. Gemcitabine and capecitabine doses were
reduced by 25% if either grade 2 neutropenia or thrombocytope-
nia occurred. Treatment was delayed for a maximum of 2 weeks if
neutropenia, thrombocytopenia, anaemia or non-haematological
toxicity of grade 3 or more was present. In the case of grade 4
neutropenia and/or thrombocytopenia, the doses of gemcitabine
and capecitabine were reduced by 25% in subsequent cycles. Tox-
icity assessment and the measurement of haematological function
were performed weekly. Renal and hepatic function was checked
before each cycle. Systemic chemotherapy consisted of gemcitab-
ine alone (1000 mg/m2) given on a weekly basis or combined with
cisplatin (75 mg/m2 every 3 weeks) or oxaliplatin (100 mg/m2 on
day 2 every 14 days).
Patients were divided into two groups: group 1 included those
submitted to RFA as up-front treatment and group 2 included
those who received RFA as a secondary treatment.
Statistics
Overall survival (OS) was calculated from the date of the diagnosis
to death from any cause using Kaplan–Meier survival analysis. The
median survival value and 95% confidence interval was calcu-
lated. Uni- and multivariable variable analyses, using log-rank15
and logistic regression16 methods, were performed to identify
factors related to survival. Statistical analysis was performed using
the statistical package SPSS for Windows, version 13.0 (SPSS Inc.,
Chicago, IL, USA). P-values of less than 0.05 were considered
statistically significant.
Results
Between February 2007 and December 2011, 168 consecutive eli-
gible patients with locally advanced pancreatic adenocarcinoma
underwent RFA. In total, 107 patients were eligible for at least 18
months of follow-up. Patients were divided into two groups
(Fig. 1): group 1 (47 patients) included those referred for RFA as
a primary treatment; and group 2 (60 patients) those who under-
went RFA after other treatments. Post-operative treatments of
group 1 were: chemo-radiotherapy (25 patients), chemotherapy
(15 patients), chemo-radiotherapy + IASC (3 patients) and IASC
alone (1 patient). Pre-operative treatments of group 2 were:
chemotherapy (47 patients), chemo-radiotherapy (7 patients),
chemo-radiotherapy + IASC (4 patients), chemotherapy + IASC
(1 patient) and IASC (1 patient). Post-operative treatments after
RFA were: chemo-radiotherapy (20 patients), chemotherapy
(18 patients), chemo-radiotherapy + IASC (11 patients) and IASC
(11 patients).
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Patient characteristics are summarized in Table 1. RFA-related
complications are summarized in Table 2. The overall post-
operative mortality rate was 1.8%: one death from hepatic failure
after a long course of chemotherapy and one death from sepsis
after a duodenal perforation. The post-operative course was
uneventful in 75.0% of patients. The overall morbidity rate was
28.0% of which the abdominal complications rate was 26.1%.
Among these, 17.7% were considered RFA-related complications
caused by thermal injuries. Specific morbidity related to surgery
was 8.4%. Four patients (3.7%) developed multiple complications
and in two of these patients a re-laparotomy was necessary
because of intra-abdominal bleeding.
Neoadjuvant therapies did not affect the complication rate (P =
0.2). A temperature >90°C applied to the tumour was found to be
the only independent factor related to complications. No differ-
ences in terms of the number of applications, type of needle and
time of procedure were found to be relevant.
Among patients receiving RCT, 1/73 (1.3%) developed grade 3
haematological toxicity requiring a 1-week rest period, 10/73
(13.6%) developed grade 2 haematological toxicity and 14/73
(19.1%) grade 2 gastrointestinal toxicity. One patient (1.3%)
developed grade 3 gastrointestinal toxicity.
Of the IASC patients, haematological toxicity was the most
common complication that developed in 25/35patients (71.4%),
with 8/35 (22.8%) of grade 3–4 neutropenia without febrile com-
plications; grade 3–4 thrombocytopenia in 6/35 (17.1%) without
bleeding; and grade 3 anaemia in 2 patients (5.7%).
Among the non-haematological toxicities, 4/35 (11.4%) devel-
oped grade 2 mucositis, 4/35 (11.4%) grade 2 nausea and vomit-
ing, 3/35 (8.6%) grade 2 hand and foot syndrome and mild
cisplatin-related peripheral sensory neurotoxicity in 4/35
(11.4%). No toxicity related to the angiographic procedure was
observed.
The median OS was 25.6 months (19.3–31.9). Fifty-three
patients had an OS greater than 20 months. Four patients were
resected after the new multimodal protocol: 2 patients died from
disease at 28 months, one is currently progression free after 47
months and one is disease free after 51 months. Patients in group
1 presented with a median survival of 14.7 months (11.3–18.1)
compared with 25.6 months (16.1–35.1) in group 2. The 32
patients undergoing the triple approach strategy had a median
survival of 34.0 months (29.1–38.9), compared with an OS rate of
18.4 months (13.3–23.5) in all other patients.
Discussion
Pancreatic cancer has been found to be one of the most aggressive
tumours with a very high rate of early progression(s). Locally
advanced stages have been treated so far with multiple approaches
such as aggressive surgerywith vascular grafts andmultiple chemo-
radiotherapy schemes but prognosis still remains very poor.
In spite of all the disheartening results, OS should be the
primary end point of clinical trials, especially in series of poor
prognosis patients, as in pancreatic cancer. Both Evaluation Cri-
teria in Solid Tumours (RECIST) and WHO criteria, which con-
sider volume reduction as a positive response, are inadequate for
pancreatic cancer and they are not related to effective prognosis.
Furthermore, progression-free survival, although very important
in the definition of the best chemotherapy approach, can intro-
duce additional bias related to the wide variability in terms of time
to diagnosis. With such a large number of variables, a single-arm
study can usually be conducted and in keeping with the data from
the literature as a control arm.1,17
The OS of the whole group of 25.6months was encouraging but
patients treated with RFA as an up-front treatment had a poorer
OS compared those who received RFA as second-line treatment.
Pre-operative chemotherapy allows the identification and exclu-
sion of patients with an early progression of disease and whomost
likely represent a non-responder category to treatment and inap-
propriate candidates for invasive treatments. This does not neces-
sarily imply that chemotherapy before RFA adds a statistical bias
of selection but, instead, given that 30% of patients with LAPC
have occult metastases at diagnosis, chemotherapy could actually
represent the best option.10
The morbidity rate related to associated surgery was 8.4% in
keeping with the literature related to surgical palliation of pancre-
atic cancer.18 RFA-related complications do not differ between
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Figure 1 Flow diagram. RFA, radiofrequency ablation; RCT, radio-
chemotherapy; IASC, intra-arterial chemotherapy combined with
systemic chemotherapy
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those who underwent RFA as an up-front or secondary treatment.
No other factors were found to be relevant in predicting compli-
cations. The temperature applied to the tumour seems to be the
only important consideration (90 °C instead of 105 °C, as nor-
mally applied to liver metastasis).8 Cumulative toxicity was not
found to be related to the multiple associations of drugs and
therapies.
Chemo-radiotherapy has been shown to be effective in local
disease control.19 Conceptually, the presence of a viable tumoural
residue at the periphery of the treated area represents a peculiar
aspect of the procedure, in which ablation must respect a ‘security
edge’ to avoid thermal injury to nearby organs and vessels.9 Radio-
therapy is proposed to treat, in particular, the viable residue.
Another important factor to take into account is that RFA, by
destroying the tumour using thermal coagulation and protein
denaturation, leads to apoptosis which enhances the immune
response by recruiting immune cells and releasing tumour anti-
gens.20,21 It has been found that thermal ablation of solid tumours
triggers an anti-tumour-specific immunity response which can be
very effective in a primary tumour and in metastasis control.
Based on this evidence, RFA could hypothetically act as an
enhancer of additional therapies.
The pharmacological rational for regional drug delivery is to
increase drug concentrations at tumour sites and reduce compli-
cations owing to systemic drug exposure.22 In a phase III study, an
intra-arterial four-drug regimen (5-fluorouracil, folic acid, epiru-
bicin and carboplatin) improved the OS in patients with LAPC
compared with systemic gemcitabine.23 A similar four-drug
approach (intra-arterial epirubicin and cisplatin plus systemic
gemcitabine and capecitabine) has also shown to be well tolerated
as a second-line treatment.24–26
The triple approach strategy (RFA plus RCT plus IASC) is a new
multi-step therapeutic approach with a good overall median sur-
vival of 34 months and represents one of the longest survival rates
for LAPC reported in literature. In the past 20 years, a large
number of patients have been treated in several randomized-
controlled phase III trials, even although the real benefit in term of
survival still remains very poor, with a median OS ranging from 8
to 13 months.1,27
The decision to give systemic chemotherapy rather than IASC
was based on the clinician’s choice, and may have added further
bias thereby limiting the conclusions that can be made. Further
studies are planned to confirm the feasibility and efficacy of this
triple approach as well as basic science investigation of the hypo-
thetical immunity reactions.
In conclusion, systemic chemotherapy plays an important role
as an up-front treatment of locally advanced pancreatic carci-
noma. RFA has to be applied in all patients with stable disease after
a short neoadjuvant treatment. Conceptually, radiotherapy is
mandatory to complete the destruction of the whole tumour or, at
least, to keep under control the viable safety residue. All patients
with good response need to be addressed to IASC after the previ-
ous steps.
A randomized controlled trial is planned to define the real
impact of RFA on prognosis compared with traditional
approaches.
Table 1 Patients characteristics
RFA up-front RFA secondary treatment
(Group 1: n = 47) (Group 2: n = 60)
Median age (years) 68.9 (53.0–83.0) 60.3 (44.7–77.5)
Gender ratio (M : F) 26:21 34:26
Tumour site
Head 31 43
Body-tail 16 17
Median tumour size (mm) 40.0 (15.0–65.0) 35.0 (15.0–70.0)
Baseline CA 19-9 (u/ml) 186 (4–3540) 132 (1–2555)
RFA, radiofrequency ablation; CA 19-9, carbohydrate antigen 19-9.
Table 2 RFA complications
n patients
Abdominal complications
RFA related
Pancreatic fistula 6 (5.6%)
Acute pancreatitis 3 (2.8%)
Portal vein thrombosis 5 (4.7%)
Duodenal injury 3 (2.8%)
Other 2 (1.9%)
Surgery-related
Biliary fistula 4 (3.7%)
Haemoperitoneum 2 (1.9%)
Other 3 (2.8%)
Systemic complications
Liver failure 1 (0.9%)
Psychosis 1 (0.9%)
RFA, radiofrequency ablation.
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